Friday, November 05, 2021 – 06:45am
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models
This forum focuses on the interdisciplinary and cutting-edge technologies...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021
As the world’s second largest medical market, ...
Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid.
Share Article
On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
The 3rd CMC-China 2021
Time: September 29-30, 2021
Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China.
Synergy of Centralized China’s Drug Volume-ba...